Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

NCT04735068 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
KRAS Mutation-Related Tumors

Interventions

DRUG: Binimetinib Pill
DRUG: Hydroxychloroquine Pill

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]